It s Time for a Chief Adherence Officer

The pharma revenue engine is stalling. A full 78% of Americans, according to the Kaiser Health Tracking Poll , say drug companies making too much money is a major reason why their healthcare costs have been rising, up from 62% who felt that way in 2014. The political winds have shifted and Powered by WPeMatico Continue reading It s Time for a Chief Adherence Officer

Pharma’s Image Fix: Lessons from the Field

The importance of an “adaptive” command style in pharma today Lieutenant General (Ret) Rick Lynch, US Army and Bob Jansen, CEO of Zensights, Pharm Exec Editorial Advisory Board member, and former president and general manager of Source Healthcare Analytics, a Symphony Powered by WPeMatico Continue reading Pharma’s Image Fix: Lessons from the Field

Accentuate the Positive: Tackling Pharma s Reputation Problem

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to stakeholders Merck s Head Defends Drug Prices, ran The New York Times headline. The Times was reporting on the Merck & Co. president s Powered by WPeMatico Continue reading Accentuate the Positive: Tackling Pharma s Reputation Problem

The Innovation Distinction: Biopharma’s Reputational Pass

Fair or not, biotech has managed to elude perception crosshairs While traditional pharmaceutical companies are taking a reputational hit, biotech organizations, for the most part, are getting a public-perception pass for now. Whether or not it s fair, or accurate, in ge Powered by WPeMatico Continue reading The Innovation Distinction: Biopharma’s Reputational Pass